Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2001;104:1594-1597

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liao, R.
Right arrow Articles by Apstein, C. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liao, R.
Right arrow Articles by Apstein, C. S.
Related Collections
Right arrow Myocardial cardiomyopathy disease

(Circulation. 2001;104:1594.)
© 2001 American Heart Association, Inc.


Brief Rapid Communications

Infusion of Light Chains From Patients With Cardiac Amyloidosis Causes Diastolic Dysfunction in Isolated Mouse Hearts

Ronglih Liao, PhD; Mohit Jain; Paige Teller, MA; Lawreen H. Connors, PhD; Soeun Ngoy; Martha Skinner, MD; Rodney H. Falk, MD; Carl S. Apstein, MD

From the Cardiac Muscle Research Laboratory (R.L., M.J., P.T., S.N., C.S.A.) and the Amyloid Treatment and Research Program (R.L., L.H.C., M.S., R.H.F., C.S.A.), Department of Medicine, Boston University School of Medicine, Boston, Mass.

Correspondence and reprint requests to Dr Ronglih Liao, 650 Albany Street, X726, Boston, MA 02118. E-mail rliao{at}bu.edu

Background— Primary (AL) amyloidosis is a plasma cell dyscrasia characterized by clonal production of immunoglobulin light chains (LC) resulting in the subsequent systemic deposition of extracellular amyloid fibrils. Cardiac involvement is marked by the hemodynamic pattern of impaired diastolic filling and restrictive cardiomyopathy. Although cardiac death in patients with AL amyloidosis is usually associated with extensive myocardial infiltration, the infiltration alone does not correlated with the degree of heart failure or survival. We hypothesized that circulating monoclonal LC may directly impair cardiac function, in addition to any mechanical effects of amyloid fibril deposition. Therefore, we examined the effects of amyloid LC proteins on diastolic and systolic cardiac function, as measured in an isolated mouse heart model.

Methods and Results— LC were obtained from patients with nonamyloid disease or from those with noncardiac, mild cardiac, and severe cardiac involved AL amyloidosis. Saline or LC (100 µg/mL) was infused into a Langendorff-perfused, isovolumically contracting mouse heart. Saline and control, noncardiac, and mild-cardiac LC infusions did not alter ex vivo cardiac function. In contrast, infusion of sever cardiac LC resulted in marked impairment of ventricular relaxation with preservation of contractile function.

Conclusion— These results demonstrate that infusion of LC from patients with AL amyloidosis result in diastolic dysfunction similar to that observed in patients with cardiac involved AL amyloidosis, and they suggest that amyloid LC proteins may contribute directly to the pathogenesis and the rapid progression of amyloid cardiomyopathy, independent of extracellular fibril deposition.


Key Words: amyloidosis • physiology • mice • heart • diastole




This article has been cited by other articles:


Home page
Nephrol Dial TransplantHome page
P. Ronco and P. Aucouturier
Renal involvement in AL amyloidosis: the facts, the promise and the hope
Nephrol. Dial. Transplant., October 1, 2009; 24(10): 2967 - 2969.
[Full Text] [PDF]


Home page
CirculationHome page
D. Feng, I. S. Syed, M. Martinez, J. K. Oh, A. S. Jaffe, M. Grogan, W. D. Edwards, M. A. Gertz, and K. W. Klarich
Intracardiac Thrombosis and Anticoagulation Therapy in Cardiac Amyloidosis
Circulation, May 12, 2009; 119(18): 2490 - 2497.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
L. M. Dember
Modern Treatment of Amyloidosis: Unresolved Questions
J. Am. Soc. Nephrol., March 1, 2009; 20(3): 469 - 472.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
D Bellavia, P A Pellikka, T P Abraham, G B Al-Zahrani, A Dispenzieri, J K Oh, R E Espinosa, C G Scott, C Miyazaki, and F A Miller
'Hypersynchronisation' by tissue velocity imaging in patients with cardiac amyloidosis
Heart, February 1, 2009; 95(3): 234 - 240.
[Abstract] [Full Text] [PDF]


Home page
Circ Heart FailHome page
A. Biolo, S. Ramamurthy, L. H. Connors, C. J. O'Hara, H. K. Meier-Ewert, P. T. Soo Hoo, D. B. Sawyer, D. S. Seldin, and F. Sam
Matrix Metalloproteinases and Their Tissue Inhibitors in Cardiac Amyloidosis: Relationship to Structural, Functional Myocardial Changes and to Light Chain Amyloid Deposition
Circ Heart Fail, November 1, 2008; 1(4): 249 - 257.
[Abstract] [Full Text] [PDF]


Home page
Br. J. Radiol.Home page
T BRAHMBHATT, P HARI, M CINQUEGRANI, N KUMAR, R KOMOROWSKI, and R Q MIGRINO
Delayed enhancement on cardiac MRI in a patient with multiple myeloma without amyloidosis
Br. J. Radiol., November 1, 2008; 81(971): e272 - e275.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
D. Feng, W. D. Edwards, J. K. Oh, K. Chandrasekaran, M. Grogan, M. W. Martinez, I. I. Syed, D. A. Hughes, J. A. Lust, A. S. Jaffe, et al.
Intracardiac Thrombosis and Embolism in Patients With Cardiac Amyloidosis
Circulation, November 20, 2007; 116(21): 2420 - 2426.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
E. Kastritis, A. Anagnostopoulos, M. Roussou, S. Toumanidis, C. Pamboukas, M. Migkou, A. Tassidou, I. Xilouri, S. Delibasi, E. Psimenou, et al.
Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone
Haematologica, October 1, 2007; 92(10): 1351 - 1358.
[Abstract] [Full Text] [PDF]


Home page
Eur J Heart FailHome page
S. Ghio, S. Perlini, G. Palladini, N. A. Marsan, G. Faggiano, M. Vezzoli, C. Klersy, C. Campana, G. Merlini, and L. Tavazzi
Importance of the echocardiographic evaluation of right ventricular function in patients with AL amyloidosis
Eur J Heart Fail, August 1, 2007; 9(8): 808 - 813.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
L. M. Dember
Amyloidosis-Associated Kidney Disease
J. Am. Soc. Nephrol., December 1, 2006; 17(12): 3458 - 3471.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
R. H. Falk
Diagnosis and Management of the Cardiac Amyloidoses
Circulation, September 27, 2005; 112(13): 2047 - 2060.
[Full Text] [PDF]


Home page
Arch Intern MedHome page
B. Ng, L. H. Connors, R. Davidoff, M. Skinner, and R. H. Falk
Senile Systemic Amyloidosis Presenting With Heart Failure: A Comparison With Light Chain-Associated Amyloidosis
Arch Intern Med, June 27, 2005; 165(12): 1425 - 1429.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
D. A. Brenner, M. Jain, D. R. Pimentel, B. Wang, L. H. Connors, M. Skinner, C. S. Apstein, and R. Liao
Human Amyloidogenic Light Chains Directly Impair Cardiomyocyte Function Through an Increase in Cellular Oxidant Stress
Circ. Res., April 30, 2004; 94(8): 1008 - 1010.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
G. Palladini, C. Campana, C. Klersy, A. Balduini, G. Vadacca, V. Perfetti, S. Perlini, L. Obici, E. Ascari, G. M. d'Eril, et al.
Serum N-Terminal Pro-Brain Natriuretic Peptide Is a Sensitive Marker of Myocardial Dysfunction in AL Amyloidosis
Circulation, May 20, 2003; 107(19): 2440 - 2445.
[Abstract] [Full Text] [PDF]